Login | Register

Brodalumab For Moderate To Severe Psoriasis Moving Into Phase III

Results from a Phase II, randomized, double-blind, placebo-controlled, dose-ranging trial designed to evaluate the efficacy and safety of brodalumab (formerly AMG 827) in 198 patients with moderate to severe plaque psoriasis have been published in the New England Journal of Medicine...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *